Prosecution Insights
Prosecution Insights
Tech Center 1600 • Art Units: 1623 1651 1693
This examiner grants 51% of resolved cases
Samuel Leonard Galster serves in Tech Center 1600 and Art Unit 1623. He has 114 resolved cases. The allowance rate for these cases is 50.9 percent. This figure represents the likelihood of an application resulting in a patent grant. The 114 resolved cases provide a solid statistical foundation for this allowance rate.
The interview lift is 43.2 percent. This metric shows the increase in the probability of allowance when an interview is conducted. By comparing the 43.2 percent lift to the 50.9 percent allowance rate, practitioners can assess the impact of verbal advocacy. The data suggests that interviews provide a measurable benefit for applications assigned to Art Unit 1623.
The median days to allowance is 1178. This value indicates the typical duration of the examination process for successful applications. The 1178-day median is a relevant factor for applicants to consider when managing their patent portfolios. These metrics, from the 114 resolved cases to the 50.9 percent allowance rate, characterize the examiner's work in Tech Center 1600.
| App # | Title | Status | Assignee |
|---|---|---|---|
| 18723131 | PROCESS FOR THE BACKBONE DEPROTECTION OF OLIGONUCLEOTIDES CONTAINING A TERMINAL ALKYL PHOSPHONATE GROUP | Non-Final OA | NOVO NORDISK A/S |
| 18539559 | OIL-RESISTANT AGENT | Final Rejection | DAIKIN INDUSTRIES, LTD. |
| 18627239 | DOSING REGIMENS FOR USE IN PREVENTING RELAPSE OF ACUTE MYELOID LEUKEMIA FOLLOWING ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION WITH VENETOCLAX IN COMBINATION WITH AZACITIDINE | Non-Final OA | ABBVIE INC. |
| 18571126 | TUNABLE DYNAMIC AND NON-DYNAMIC HYDROGEL SYSTEMS | Non-Final OA | The Johns Hopkins University |
| 19380466 | 4'-HALOGEN CONTAINING NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS AND USES RELATED THERETO | Final Rejection | EMORY UNIVERSITY |
| 18558874 | NUCLEOTIDE AND NUCLEOSIDE THERAPEUTIC COMPOSITIONS, COMBINATIONS AND USES RELATED THERETO | Final Rejection | EMORY UNIVERSITY |
| 18255757 | STABLE AQUEOUS COMPOSITION FOR PRETERM TO PROMOTE EARLY POSTNAL GROWTH | Non-Final OA | SOCIETE DES PRODUITS NESTLE S.A. |
| 17616966 | METHODS OF REJUVENATING AGED TISSUE BY INHIBITING 15-HYDROXYPROSTAGLANDIN DEHYDROGENASE (15-PGDH) | Final Rejection | The Board of Trustees of the Leland Stanford Junior University |
| 18543979 | DISULFIDE CONTAINING THERAPEUTICS | Non-Final OA | Singular Genomics Systems, Inc. |
| 18269213 | MOLECULE FOR INDUCING SPONTANEOUS CALCIFICATION OF TUMOR CELLS AND USE THEREOF | Final Rejection | ZHEJIANG UNIVERSITY |
| 17291588 | METHODS FOR CONSOLIDATING ANTIBIOTIC-ELUTING POLYMERIC MATERIALS | Non-Final OA | THE GENERAL HOSPITAL CORPORATION |
| 18571905 | ANTI-FUNGAL COMPOSITION DERIVED FROM HESPERALOE | Final Rejection | Kimberly-Clark Worldwide, Inc. |
| 17633254 | HYBRID AMIDE DERIVATIVES OF AMPHOTERICIN B | Final Rejection | The Board of Trustees of the University of Illinois |
| 17265387 | METHODS FOR REDUCING ABNORMAL SCAR FORMATION | Non-Final OA | CORNELL UNIVERSITY |
| 17918725 | THYCLOTIDES | Non-Final OA | The United States of America,as represented by the Secretary,Department of Health and Human Services |
| 18317564 | COMPOSITIONS AND METHODS FOR ALLEVIATING CONDITIONS CAUSED BY ABNORMAL SUBCUTANEOUS DEPOSIT OF ADIPOSE TISSUE OR FAT | Non-Final OA | Caliway Biopharmaceuticals Co., Ltd. |
| 18263124 | NOVEL METHOD FOR PRODUCING ANTIBODY-IMMUNOSTIMULATOR CONJUGATE | Non-Final OA | Daiichi Sankyo Company, Limited |
| 18252838 | COMPLEX OF BETA-GLUCAN AND NUCLEIC ACID HAVING CONTROLLED PARTICLE SIZE | Final Rejection | DAIICHI SANKYO COMPANY, LIMITED |
| 17972909 | METHODS OF DOSING OF APICAL SODIUM-DEPENDENT BILE ACID TRANSPORTER INHIBITORS (ASBTIs) | Non-Final OA | Mirum Pharmaceuticals, Inc. |
IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.
Build Your Strategy